FLT3 Mutations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Multi-Center Analysis
Year: 2026
Type: article
Study design: Observational Study
Abstract: FLT3 mutations are established high-risk drivers in acute myeloid leukemia (AML), but their role in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) remains poorly defined. We assembled 115 patients with FLT3-mutant MDS (n=63) or CMML (n=52) across six academic institutions and compared clinicogenomic features and outcomes with FLT3-wildtype controls using propensity score matching and multivariable modeling. FLT3-mutant MDS and CMML displayed a proliferative phenotype, with higher white blood cell counts, increased frequency of CMML-2, and significantly higher rates of AML transformation. FLT3-mutant MDS was enriched for signaling co-mutations, such as NRAS, PTPN11, and CBL, whereas FLT3-mutant CMML showed frequent co-mutation with ASXL1 and SRSF2. FLT3 mutations were independently associated with inferior survival in both entities. After matching, FLT3-mutant MDS had worse median overall survival (OS: 19.9 vs 44.2 months, p=0.046) and leukemia-free survival (LFS: 13.8 vs 37.1 months, p=0.023). In CMML, median OS was 30.4 vs 67.2 months (p=0.017) and LFS 17.2 vs 65.6 months (p=0.014). FLT3-TKD was associated with more favorable outcomes than FLT3-ITD. FLT3-targeted therapy was associated with longer survival in unadjusted comparisons (median OS 14.3 vs 45.9 months in MDS; 20.6 vs 35.0 months in CMML), although this association was attenuated and no longer statistically significant after accounting for immortal time bias introduced from variable treatment initiation timing (adjusted time-dependent HR 0.66, MDS; 0.64, CMML). These findings support early identification of FLT3-mutant MDS and CMML and highlight the need for prospective studies evaluating early therapeutic intervention in this high-risk molecular subset.
Source: Blood Advances
Authors: Juan Jose Rodríguez-Sevilla, Kelly S Chien, Ziyi Li, Fatima Zahra Jelloul, Ruoxing Li, Najla Al-Ali, David A. A Sallman, Rashmi Kanagal-Shamanna, Clifford M Csizmar, Abhishek A. Mangaonkar, Mrinal M. Patnaik, Andrés Jerez, Maria Julia Montoro, David Valcárcel, Marina Cornejo Garcia, Sandra Castaño-Díez, Marina Díaz-Beyá, Jordi Esteve, Mónica Del Rey, María Díez-Campelo, Xavier Calvo, Francesc Sole, Eric Padron, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Rami S. S. Komrokji
Institutions: The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Mayo Clinic, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Universidad de Salamanca, Hospital Del Mar, Josep Carreras Leukaemia Research Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,800
OpenAlex ID: W7237260696
